IAS 2022: Metabolic complications of newer HIV drugs in older people
1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.
Lipodystrophy and metabolic complications
INSTIs and cardiovascular events in the RESPOND cohort: early increase at six months normalises after two years
1 July 2022. Related: Side effects, Lipodystrophy and metabolic complications.
Weight changes on ART and how to lose weight successfully
1 June 2021. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Nutrition.
Tesamorelin for NAFLD in people living with HIV
13 December 2019. Related: Lipodystrophy and metabolic complications, Hepatitis coinfection.
Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial
15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Over half of mostly black US HIV group has NAFLD – and many have NASH
18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.
Type 2 diabetes is often undermanaged in HIV positive people
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
INSTI and weight gain: reports from CROI 2019
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
9th International Workshop on HIV and Ageing
19 October 2018. Related: Conference reports, Lipodystrophy and metabolic complications, Coinfections and complications.
Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir
8 June 2018. Related: Side effects, Lipodystrophy and metabolic complications.
Reducing risk of myocardial infarction (MI) in HIV positive people
16 April 2018. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison
1 December 2013. Related: Conference reports, Lipodystrophy and metabolic complications.
No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Lipodystrophy and metabolic complications.
Intestinal microflora and low grade metabolic inflammation
1 February 2011. Related: Conference reports, Lipodystrophy and metabolic complications.
Complex connections between bone and fat metabolism
1 February 2011. Related: Conference reports, PK and drug interactions, Lipodystrophy and metabolic complications.
UK studies on bone health: increasedfracture rates reported in HIV-positive people
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, 4-6 November 2010, London
1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.
Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Age raises fracture risk more in HIV-positive people
1 December 2010. Related: Conference reports, Lipodystrophy and metabolic complications.
FDA approves tesamorelin for reduction of central fat accumulation
1 December 2010. Related: Side effects, Lipodystrophy and metabolic complications.
Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US
1 October 2010. Related: Side effects, Lipodystrophy and metabolic complications.
75% HIV-positive children have insufficient levels of Vitamin D
1 June 2010. Related: Conference reports, Paediatric care, Side effects, Lipodystrophy and metabolic complications.
High rates of osteopenia and osteoporosis: importance of DEXA monitoring
1 June 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients
2 April 2010. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.
Clinical benefits of stopping smoking: CVD and CHD risk returns to that of previous smoker in HIV-positive people within three years
2 April 2010. Related: Conference reports, Lipodystrophy and metabolic complications, Cancer and HIV.
Vitamin D deficiencies in HIV management
2 April 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men
21 February 2010. Related: Conference reports, Women's health, Side effects, Lipodystrophy and metabolic complications.
Gender and race differences in lipodystrophy symptoms
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Raltegravir body composition study: 48-week DEXA results
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lipid and metabolic changes with ARV combinations
5 October 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy
26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Statin use in HIV-positive patients
26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
New-fill used to treat lipoatropy in feet
12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Growth hormone release factor (TH9507) reduces central fat adiposity
4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Interventions for the management of lipodystrophy and metabolic complications
25 March 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Uridine supplement reverses thymidine-induced lipoatrophy
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Niacin has beneficial effect on lipids but no reduction in abdominal fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Gluteal implants used to replace lost buttock fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Omega-3 supplement effective to reduce triglycerides
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
rHGH reduces central fat accumulation in adolescent lipodystrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pravastatin improves lipid profiles but not endothelial function
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Improvement of lipids following switch to tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Restorative treatments for HIV-associated lipoatrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Vancouver researchers urge caution with combinations of lipid drugs
6 November 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Diabetes and HIV and HCV; aging/HIV and diabetes
2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
FDA panel recommends approval of New-Fill
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy regresses in three patients switched to atazanavir
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.